Effect of pioglitazone on altered expression of Aβ metabolism-associated molecules in the brain of fructose-drinking rats, a rodent model of insulin resistance

European Journal of Pharmacology

Volumn 664, Issue 1-3, 2011, Pages 14-19

  Luo, Dingzhen ^a   Hou, Xunyao ^a   Hou, Liang ^a   Wang, Meixia ^a   Xu, Song ^a   Dong, Chuanfang ^a   Liu, Xueping ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

amyloid; Insulin resistance; Pioglitazone

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE 1; BRAIN PROTEIN; FRUCTOSE; GAMMA SECRETASE; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; PIOGLITAZONE;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN DYSFUNCTION; CONTROLLED STUDY; DIET; DISEASE COURSE; DRUG MECHANISM; ENZYME ACTIVITY; FEEDING; HIPPOCAMPUS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; TREATMENT DURATION; WISTAR RAT;

AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRINKING; FRUCTOSE; GENE EXPRESSION REGULATION; HIPPOCAMPUS; INSULIN; INSULIN RESISTANCE; MALE; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; THIAZOLIDINEDIONES;

EID: 79957909052     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.04.045     Document Type: Article

References (32)

1. Bann, H.F., Higgins, P.J., 1981. Reaction of monosaccharides with proteins: possible evolutionary significance. Science 213, 222-224. (Pubitemid 11060569)
2. Brownlee, M., Cerami, A., Vlassara, H., 1988. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318, 1315-1321.
3. Craft, S., 2005. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol. Aging 26, 65-69.
4. Craft, S., 2006. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis. Assoc. Disord. 20, 298-301.
5. Craft, S., Peskind, E., Schwartz, M.W., Schellenberg, G.D., Raskind, M., Porte Jr., D., 1998. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50, 164-168.
6. Gaikwad, A.B., Viswanad, B., Ramarao, P., 2007. PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin in thoracic aorta isolated from rats with insulin resistance. Pharmacol. Res. 55, 400-407.
7. Gasparini, L., Gouras, G.K., Wang, R., Gross, R.S., Beal, M.F., Greengard, P., Xu, H., 2001. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 21, 2561-2570. (Pubitemid 32298198)
8. Gasparini, L., Netzer, W.J., Greengard, P., Xu, H., 2002. Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol. Sci. 23, 288-293. (Pubitemid 34655735)
9. Goedert, M., Spillantini, M.G., 2006. A century of Alzheimer's disease. Science 314, 777-781.
10. Heneka, M.T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., Landreth, G.E., 2005. Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV717I transgenic mice. Brain 128, 1442-1453. (Pubitemid 40826196)
11. Ho, L., Qin, W., Pompl, P.N., Xiang, Z., Wang, J., Zhao, Z., Peng, Y., Cambareri, G., Rocher, A., Mobbs, C.V., Hof, P.R., Pasinetti, G.M., 2004. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 18, 902-924.
12. Hoyer, S., 2004. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol. 490, 115-125.
13. Iwai, H., Ohno, Y., Aoki, N., 2003. The effect of leptin, tumor necrosis factor-alpha (TNFalpha), and nitric oxide (NO) production on insulin resistance in Otsuka Long-Evans fatty rats. Endocr. J. 50, 673-680. (Pubitemid 38139950)
14. Jaya Prasanthi, R.P., Schommer, E., Thomasson, S., Thompson, A., Feist, G., Ghribi, O., 2008. Regulation of beta-amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer's disease. Mech. Ageing Dev. 129, 649-655.
15. Jolivalt, C.G., Lee, C.A., Beiswenger, K.K., Smith, J.L., Orlov, M., Torrance, M.A., Masliah, E., 2008. Defective insulin signaling pathway and increased glycogen synthase kinase- 3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J. Neurosci. Res. 86, 3265-3274.
16. Ke, Y.D., Delerue, F., Gladbach, A., Götz, J., Ittner, L.M., 2009. Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 4, e7917.
17. Kloppenborg, R.P., van den Berg, E., Kappelle, L.J., Biessels, G.J., 2008. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur. J. Pharmacol. 585, 97-108.
18. Ling, Y., Morgan, K., Kalsheker, N., 2003. Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. Int. J. Biochem. Cell Biol. 35, 1505-1535.
19. Liu, X., Luo, D., Zheng, M., Hao, Y., Hou, L., Zhang, S., 2010. Effect of pioglitazone on insulin resistance in fructose-drinking rats correlates with AGEs/RAGE inhibition and block of NADPH oxidase and NF kappa B activation. Eur. J. Pharmacol. 629, 153-158.
20. Luchsinger, J.A., 2008. Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. Eur. J. Pharmacol. 585, 119-129.
21. Mattson, M.P., 2004. Pathways towards and away from Alzheimer's disease. Nature 430, 631-639. (Pubitemid 39061671)
22. Mosconi, L., 2005. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 32, 486-510.
23. Rivera, E.J., Goldin, A., Fulmer, N., Tavares, R., Wands, J.R., de La Monte, S.M., 2005. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J. Alzheimers Dis. 8, 247-268.
24. Selkoe, D.J., 2001. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J. Alzheimers. Dis. 3, 75-80.
25. Sinha, S., Lieberburg, I., 1999. Cellular mechanisms of beta-amyloid production and secretion. Proc. Natl. Acad. Sci. 96, 11049-11053.
26. Storer, P.D., Xu, J., Chavis, J., Drew, P.D., 2005. Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J. Neuroimmunol. 161, 113-122. (Pubitemid 40340879)
27. Suzuki, M., Nomura, C., Odaka, H., Ikeda, H., 1997. Effect of an insulin sensitizer, pioglitazone, on hypertension in fructose-drinking rats. Jpn. J. Pharmacol. 74, 297-302.
28. Timmer, N.M., Kuiperij, H.B., de Waal, R.M., Verbeek, M.M., 2010. Do amyloid β- associated factors co-deposit with Aβ in mouse models for Alzheimer's disease? J Alzheimers Dis. 22, 345-355.
29. Watson, S., Craft, S., 2003. The role of insulin resistance in the pathogenesis of Alzheimer's disease implications for treatment. CNS Drugs 17, 27-45. (Pubitemid 36044347)
30. Zhao, W.Q., Alkon, D.L., 2001. Role of insulin and insulin receptor in learning and memory. Mol. Cell. Endocrinol. 177, 125-134.
31. Zhao, W.Q., Townsend, M., 2009. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim. Biophys. Acta 1792, 482-496.
32. Zhao, Z., Ho, L., Wang, J., Qin, W., Festa, E.D., Mobbs, C., Hof, P., Rocher, A., Masur, S., Haroutunian, V., Pasinetti, G.M., 2005. Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistance- associated promotion of Alzheimer's disease beta-amyloid neuropathology. FASEB J. 19, 2081-2082. (Pubitemid 41759772)